• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

anti-PLG antibody :: Mouse Plasminogen Monoclonal Antibody

Scan QR to view Datasheet
Catalog # MBS311192
Unit / Price
  1 mg  /  $535 +1 FREE 8GB USB
anti-PLG antibody
Product Name

Plasminogen (PLG), Monoclonal Antibody

Popular Item
Also Known As

MAb to Plasminogen

Product Synonym Names
Monoclonal Antibody to Human Plasminogen
Product Gene Name
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
Immunogen Sequence Length
810
Chromosome Location
Chromosome: 6; NC_000006.11 (161123225..161175086). Location: 6q26
OMIM
173350
3D Structure
ModBase 3D Structure for P00747
Clonality
Monoclonal
Isotype
IgG1
Clone Number
5H3
Host
Mouse
Specificity
Reacts with human Plasminogen, plasmin and angiostatin. Does not crossreact with other human serum proteins.
Purity/Purification
>90% pure (SDS-PAGE). Ion exchange chromatography
Form/Format
Purified, Liquid
Concentration
8.6 mg/ml (OD280nm, E0.1% = 1.4) (lot specific)
Source
Ascites
Immunogen
Purified human plasminogen
Affinity Constant
Not determined
Buffer
Phosphate Buffered Saline,pH 7.4
Preservative
0.09% Sodium azide
Important Note
Centrifuge before opening to ensure complete recovery of vial contents.
Warnings
This product contains sodium azide, which has been classified as Xn (Harmful), in European Directive 67/548/EEC in the concentration range of 0.1 - 1.0 %. When disposing of this reagent through lead or copper plumbing, flush with copious volumes of water to prevent azide build-up in drains.
Preparation and Storage
Store at 2-8°C.
ISO Certification
Manufactured in an ISO 9001:2008 Certified Laboratory.
Other Notes
Small volumes of anti-PLG antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Applications Tested/Suitable for anti-PLG antibody
EIA/ELISA, Immunohistochemistry, Immunoassay Antibody Pairs
Application Notes for anti-PLG antibody
Affinity purification of human plasminogen.
Detection of plasminogen in ELISA and immunohistochemistry.
Works in immunohistochemistry on formalin-fixed and paraffin embedded sections.

Each laboratory should determine an optimum working titer for in its particular application.

Other applications have not been tested but use in such assayss should not necessarily be excluded.
NCBI/Uniprot data below describe general gene information for PLG. It may not necessarily be applicable to this product.
NCBI GI #
NCBI GeneID
NCBI Accession #
NCBI GenBank Nucleotide #
UniProt Primary Accession #
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
plasminogen isoform 1
NCBI Official Synonym Full Names
plasminogen
NCBI Official Symbol
NCBI Official Synonym Symbols
DKFZp779M0222
  [Similar Products]
NCBI Protein Information
plasminogen; OTTHUMP00000017544; OTTHUMP00000017545; OTTHUMP00000197002
UniProt Protein Name
Plasminogen
Protein Family
UniProt Gene Name
UniProt Entry Name
PLMN_HUMAN
NCBI Summary for PLG
The protein encoded by this gene is a secreted blood zymogen that is activated by proteolysis and converted to plasmin and angiostatin. Plasmin dissolves fibrin in blood clots and is an important protease in many other cellular processes while angiostatin inhibits angiogenesis. Defects in this gene are likely a cause of thrombophilia and ligneous conjunctivitis. Two transcript variants encoding different isoforms have been found for this gene.
UniProt Comments for PLG
Function: Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells. Ref.26Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo. Ref.26

Catalytic activity: Preferential cleavage: Lys-|-Xaa > Arg-|-Xaa; higher selectivity than trypsin. Converts fibrin into soluble products. Ref.29

Enzyme regulation: Converted into plasmin by plasminogen activators, both plasminogen and its activator being bound to fibrin. Activated with catalytic amounts of streptokinase. Plasmin activity inhibited by SERPINE2. Ref.26

Subunit structure: Interacts (both mature PLG and the angiostatin peptide) with CSPG4 and AMOT. Interacts (via the Kringle domains) with HRG; the interaction tethers PLG to the cell surface and enhances its activation

By similarity. Ref.19 Ref.24 Ref.25 Ref.27 Ref.30

Subcellular location: Secreted. Note: Locates to the cell surface where it is proteolytically cleaved to produce the active plasmin. Interaction with HRG tethers it to the cell surface. Ref.24 Ref.26

Tissue specificity: Present in plasma and many other extracellular fluids. It is synthesized in the liver.

Domain: Kringle domains mediate interaction with CSPG4. Ref.25

Post-translational modification: N-linked glycan contains N-acetyllactosamine and sialic acid. O-linked glycans consist of Gal-GalNAc disaccharide modified with up to 2 sialic acid residues (microheterogeneity).In the presence of the inhibitor, the activation involves only cleavage after Arg-580, yielding two chains held together by two disulfide bonds. In the absence of the inhibitor, the activation involves additionally the removal of the activation peptide.

Involvement in disease: Defects in PLG are a cause of susceptibility to thrombosis (THR) [

MIM:188050]. It is a multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation. Ref.48 Ref.51 Ref.52 Ref.53Defects in PLG are the cause of plasminogen deficiency (PLGD) [

MIM:217090]. PLGD is characterized by decreased serum plasminogen activity. Two forms of the disorder are distinguished: type 1 deficiency is additionally characterized by decreased plasminogen antigen levels and clinical symptoms, whereas type 2 deficiency, also known as dysplasminogenemia, is characterized by normal, or slightly reduced antigen levels, and absence of clinical manifestations. Plasminogen deficiency type 1 results in markedly impaired extracellular fibrinolysis and chronic mucosal pseudomembranous lesions due to subepithelial fibrin deposition and inflammation. The most common clinical manifestation of type 1 deficiency is ligneous conjunctivitis in which pseudomembranes formation on the palpebral surfaces of the eye progresses to white, yellow-white, or red thick masses with a wood-like consistency that replace the normal mucosa. Ref.48 Ref.50 Ref.51 Ref.52 Ref.53 Ref.54 Ref.55 Ref.56

Miscellaneous: Plasmin is inactivated by alpha-2-antiplasmin immediately after dissociation from the clot.

Sequence similarities: Belongs to the peptidase S1 family. Plasminogen subfamily.Contains 5 kringle domains.Contains 1 PAN domain.Contains 1 peptidase S1 domain.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated withanti-PLG antibody
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000